HCmed to expand inhalation treatment business with new CDMO offering

The Taiwan-based nebuliser specialist has signed an MoU with Formosa Laboratories, and Formosa Pharmaceuticals to form a biopharma one-stop-shop

The tripartite agreement plans to integrate HCmed's technology in developing customised vibrating mesh nebulisers with Formosa Laboratories' drug development and production experience of APIs, ADCs, and injections, and Formosa Pharmaceuticals' APNT (Activus Pure Nanoparticle Technology) nanotechnology platform, to become a one-stop-shop in the biopharmaceutical industry as a full-service CDMO.

During the last 2 years, the COVID-19 pandemic has pushed demand for respiratory treatment drugs; it also accounts for the uptick in demand for developing respiratory drugs, so much so that several well-known global pharmaceutical companies have incorporated HCmed's proprietary mesh technology into the development of their inhaled products.

By focusing on drug-device combination products, the three parties believe their CDMO offering can provide their pharma partners with a platform to deliver drugs, and integrated services that extend to drug development, mass production, and product packaging.

According to Jason Cheng, CEO of HCmed, by delivering such services, they expect to shorten combination product development time and reduce costs, thereby creating "win-win" relationships.